English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Canada is among the leading spenders in pharmaceuticals. Based on projected fi gures, the cost of pharmaceuticals is expected to rise by another 6–12% by 2023. Approximately CAN$4.6 billion of healthcare funding is spent on biological drugs (including growth factors and monoclonal antibodies) which are commonly used in the setting of haematology and blood and marrow transplant. Aim: As healthcare funds become more scarce, a need to investigate cost-eff ective alternatives at both the federal and provincial levels to provide cancer care is imperative. Discussion: Biosimilars, also known as ‘subsequent entry biologics’ (SEBs), are cheaper alternatives to biological drugs. Biosimilars have been utilized in many European countries for years with signifi cant cost savings and no signifi cant reporting of adverse events. In Canada, there is a reluctance to use biosimilars due to the potential risk of adverse eff ects which can occur if the biosimilar is interchanged with the originator product. In keeping with this reasoning, Alberta’s stance is against substitutability or interchangeability of biosimilars/SEBs with the reference product. Conclusion: For the benefi t of cost-eff ective, quality cancer care, it is time to re-examine the use of biosimilars in our province and understand if the potential risks outweigh the benefi t of cost savings.

Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?